Capivasertib (Truqap) Now Accessible on PBS for Metastatic Breast Cancer Patients
29 Sep 2025
This decision offers patients an additional therapy when cancer becomes resistant to existing treatments and makes access more equitable, as the drug previously cost over $98,000.
Impact on Patients
BCNA Clinical Advisory Member Jenny Gilchrist highlighted the benefits of capivasertib:
“Capivasertib doubles the time women with metastatic breast cancer can live without disease progression, providing valuable extra time and improved quality of life.”
Advocacy and Policy
BCNA representatives emphasised that this PBS listing is a direct result of sustained advocacy efforts. Lisa Rankin, BCNA SATT Consumer Representative, and Vicki Durston, Director of Policy, Advocacy and Support Services, noted that while around 3,000 patients are expected to benefit, gaps remain in national data collection for metastatic breast cancer. Improved data is essential to ensure treatments reach everyone who needs them and to guide future healthcare decisions.
BCNA remains committed to advocating for equitable access to innovative treatments and better support for people living with metastatic breast cancer.
For more information or to join BCNA in advocacy efforts, contact policy@bcna.org.au.
Source: Breast Cancer Network Australia (BCNA)
